CYRX
Cryoport, Inc.Company Information
- Company Name
- Cryoport, Inc.
- CIK
- CIK0001124524
- Category
- Accelerated filer
- Ticker: Exchange
- CYRX: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- CYRX
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2026-08-11
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 327,150
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 43,835,457
- Shares outstanding
- 50,442,796
- Ownership
- 86.90%
Earnings Market Reaction
- Filing date
- 2026-08-06
- Price on filing date
- —
- 1-month reaction
- 9.38%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Convertible Preferred Stock | 0 | 0 | 0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Class B Convertible Preferred Stock | 0 | 0 | 0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Class C Convertible Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | ||||||
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 269 | 273 | 250 | 256 | 243 | 36 | 34 | 31 | 34 | 39 | 46 | 59 | ||||||
| Short Term Investments | 127 | 131 | 161 | 166 | 183 | 208 | 216 | 228 | 381 | 399 | 410 | 406 | ||||||
| Accounts Receivable Net Current | 36 | 39 | 33 | 35 | 33 | 28 | 25 | 43 | 40 | 41 | 42 | 43 | ||||||
| Inventory Net | 22 | 22 | 23 | 23 | 23 | 23 | 21 | 24 | 24 | 25 | 26 | 29 | ||||||
| Prepaid Expense And Other Assets Current | 6 | 6 | 8 | 5 | 7 | 7 | 8 | 11 | 11 | 11 | 10 | 12 | ||||||
| Assets Of Disposal Group Including Discontinued Operation Current | - | - | - | - | - | 108 | 36 | - | - | - | - | - | ||||||
| Assets Current | 460 | 471 | 476 | 485 | 489 | 411 | 342 | 350 | 502 | 526 | 535 | 549 | ||||||
| Property Plant And Equipment Net | 95 | 90 | 85 | 83 | 82 | 80 | 80 | 88 | 87 | 86 | 85 | 75 | ||||||
| Operating Lease Right Of Use Asset | 40 | 39 | 40 | 40 | 38 | 39 | 40 | 30 | 30 | 31 | 33 | 33 | ||||||
| Finite Lived Intangible Assets Net | 136 | 139 | 138 | 141 | 144 | 145 | 148 | 176 | 178 | 190 | 194 | 193 | ||||||
| Goodwill | 22 | 22 | 22 | 22 | 19 | 21 | 21 | 54 | 52 | 108 | 108 | 149 | ||||||
| Deposits Assets | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 2 | ||||||
| Deferred Income Tax Assets Net | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | ||||||
| Disposal Group Including Discontinued Operation Assets Noncurrent | - | - | - | - | - | - | 71 | - | - | - | - | - | ||||||
| Assets | 756 | 764 | 765 | 774 | 774 | 700 | 703 | 702 | 852 | 943 | 958 | 1,001 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable And Accrued Liabilities Current | 16 | 16 | 15 | 14 | 15 | 13 | 16 | 25 | 25 | 27 | 27 | 28 | ||||||
| Employee Related Liabilities Current | 12 | 17 | 13 | 11 | 9 | 13 | 11 | 11 | 11 | 14 | 11 | 10 | ||||||
| Contract With Customer Liability Current | 2 | 2 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 2 | 1 | 2 | ||||||
| Operating Lease Liability Current | 4 | 4 | 4 | 4 | 4 | 4 | 3 | 6 | 5 | 5 | 5 | 5 | ||||||
| Finance Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Convertible Debt Current | 186 | 185 | 185 | - | - | 14 | 14 | 14 | 14 | - | - | - | ||||||
| Notes Payable Current | 0 | 0 | 0 | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities Of Disposal Group Including Discontinued Operation Current | - | - | - | - | - | 28 | 15 | - | - | - | - | - | ||||||
| Business Combination Contingent Consideration Liability Current | 1 | - | - | - | - | - | 3 | 3 | 3 | - | 0 | - | ||||||
| Liabilities Current | 221 | 225 | 219 | 31 | 30 | 74 | 65 | 61 | 60 | 49 | 46 | 45 | ||||||
| Convertible Debt Noncurrent | - | - | - | 185 | 185 | 184 | 184 | 184 | 356 | 379 | 379 | 378 | ||||||
| Long Term Notes Payable | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | ||||||
| Operating Lease Liability Noncurrent | 40 | 39 | 39 | 39 | 37 | 38 | 39 | 26 | 27 | 28 | 29 | 30 | ||||||
| Finance Lease Liability Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Deferred Income Tax Liabilities Net | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 4 | 3 | 2 | 3 | 5 | ||||||
| Other Liabilities Noncurrent | 1 | 1 | 0 | 3 | 3 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | ||||||
| Business Combination Contingent Consideration Liability Noncurrent | - | 1 | 1 | 1 | 1 | 1 | 4 | 5 | 5 | 10 | 9 | 4 | ||||||
| Liabilities Of Disposal Group Including Discontinued Operation Noncurrent | - | - | - | - | - | - | 8 | - | - | - | - | - | ||||||
| Liabilities | 266 | 269 | 262 | 261 | 259 | 301 | 302 | 283 | 452 | 471 | 469 | 463 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 1,155 | 1,153 | 1,153 | 1,152 | 1,151 | 1,147 | 1,146 | 1,141 | 1,138 | 1,135 | 1,131 | 1,127 | ||||||
| Retained Earnings Accumulated Deficit | -708 | -699 | -689 | -675 | -668 | -769 | -757 | -738 | -739 | -661 | -642 | -580 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -2 | -3 | -3 | -4 | -5 | -16 | -21 | -16 | -29 | -30 | -26 | -34 | ||||||
| Stockholders Equity | 491 | 495 | 503 | 513 | 519 | 399 | 402 | 419 | 400 | 472 | 489 | 538 | ||||||
| Liabilities And Stockholders Equity | 756 | 764 | 765 | 774 | 774 | 700 | 703 | 702 | 852 | 943 | 958 | 1,001 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | ||||||
| Common Stock Shares Issued | 51 | 50 | 50 | 50 | 50 | 50 | 50 | 49 | 49 | 49 | 49 | 49 | ||||||
| Shares Outstanding | 51 | 50 | 50 | 50 | 50 | 50 | 50 | 49 | 49 | 49 | 49 | 49 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialCryoport, Inc. (CYRX) — SEC Financial Statements & Analysis
Cryoport, Inc. (CYRX) is a pharmaceutical preparations company, incorporated in NV. Cryoport, Inc. trades on Nasdaq as: CYRX. Cryoport, Inc. (CYRX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, Cryoport, Inc. carries a market cap of $791.95M, a P/E ratio of -16.71x, a P/B ratio of 1.61x, a P/S ratio of 4.25x, an enterprise value of $710.69M, and an EV/EBITDA multiple of -51.29x. On profitability, it posts a gross margin of 47.08%, an operating margin of -21.25%, a net margin of -25.41%, a Return on Equity (ROE) of -9.39%, a Return on Assets (ROA) of -6.19%, and a Return on Invested Capital (ROIC) of -8.46%. Per share, it reports EPS of $-0.94, diluted EPS of $-0.94, free cash flow per share of $-0.40, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 12.14% year-over-year, net income growth of -157.08% year-over-year, and EPS growth of -156.87% year-over-year. On the balance sheet, it maintains a current ratio of 2.08x, a quick ratio of 1.96x, working capital of $239.17M, a debt-to-equity ratio of 0.54x, a debt ratio of 0.35, an interest coverage ratio of -18.78x, free cash flow of $-20.03M (TTM), and net debt of $-81.26M. Figures sourced from SEC EDGAR.
- Market Cap
- $791.95M
- P/E TTM
- -16.71x
- EPS TTM
- $-0.94
- P/B TTM
- 1.61x
- ROE TTM
- -9.39%
- ROA TTM
- -6.19%
- Debt To Equity
- 0.54x
- Free Cash Flow TTM
- $-20.03M
- Net Revenue TTM Growth 1Y
- 12.14%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Cryoport, Inc. in?
Cryoport, Inc. (CYRX) operates in the Pharmaceutical Preparations industry.
What exchange does CYRX trade on?
Cryoport, Inc. (CYRX) trades on the Nasdaq.
Where is Cryoport, Inc. incorporated?
Cryoport, Inc. is incorporated in NV.
When was Cryoport, Inc. (CYRX)'s most recent SEC filing?
Cryoport, Inc. (CYRX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06.
What is CYRX's market cap?
Cryoport, Inc. (CYRX) has a market capitalization of $791.95M as of 2026-06-30.
What is CYRX's EPS (earnings per share)?
Cryoport, Inc. (CYRX)'s trailing twelve month EPS is $-0.94 as of 2026-06-30.
What is CYRX's ROE (return on equity)?
Cryoport, Inc. (CYRX)'s trailing twelve month Return on Equity (ROE) is -9.39% as of 2026-06-30.
What is CYRX's ROA (return on assets)?
Cryoport, Inc. (CYRX)'s trailing twelve month Return on Assets (ROA) is -6.19% as of 2026-06-30.
What is CYRX's ROIC (return on invested capital)?
Cryoport, Inc. (CYRX)'s trailing twelve month Return on Invested Capital (ROIC) is -8.46% as of 2026-06-30.
What is CYRX's EV/EBITDA?
Cryoport, Inc. (CYRX)'s trailing twelve month EV/EBITDA is -51.29x as of 2026-06-30.